NeuroOne Medical Technologies Corporation (NMTC)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2 | 0 | 0 | 2 | 3 | 12 | 10 | 10 |
| Operating profit | $m | -4 | -8 | ||||||
| Net profit | $m | -14 | -10 | -10 | -12 | -12 | -4 | -7 | -5 |
| EPS reported | $ | -0.54 | -0.91 | ||||||
| Operating cashflow per share | $ | -0.42 | -0.81 | ||||||
| Capex per share | $ | 0.01 | 0.01 | ||||||
| FCF per share | $ | -0.44 | -0.83 | ||||||
| Free cash flow | $m | -3 | -7 | ||||||
| Net debt | $m | -7 | -2 | ||||||
| Book value equity | $m | 7 | 4 | ||||||
| Book value per share | $ | 1.06 | 0.43 | ||||||
| Number of shares | m | 6.69 | 8.74 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 5.04 | 9.47 | ||||||
| P/S LTM | x | 2.95 | 3.57 | ||||||
| P/FCF LTM | x | -12.22 | -4.98 | ||||||
| EV/EBITDA LTM | x | -9.76 | -4.25 | ||||||
| EV/Sales LTM | x | 2.43 | 1.49 | ||||||
| Earnings Yield LTM | % | -10.11% | -42.55% | ||||||
| FCF Yield | % | -8.18% | -20.08% | ||||||
| Quality | |||||||||
| ROE | % | -50.98% | -126.45% | ||||||
| ROIC | % | -49.11% | -1.83% | ||||||
| Operating margin | % | -34.94% | -76.05% | ||||||
| Gross margin | % | +67.30% | +55.67% | ||||||
| FCF/Sales | % | -24.13% | -71.63% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +250.35% | +189.54% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -10.94 | -97.68 | ||||||
| Net Debt/EBITDA | x | 2.09 | 0.25 | ||||||
| EBIT/Net interest | x | -12.65 | 22.76 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.93 | -0.54 | ||||||
| Gross debt/equity | x | 0.04 | 0.02 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
NeuroOne Medical Technologies Corporation (NMTC)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free